1. Home
  2. SGA vs HURA Comparison

SGA vs HURA Comparison

Compare SGA & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGA
  • HURA
  • Stock Information
  • Founded
  • SGA 1986
  • HURA 2009
  • Country
  • SGA United States
  • HURA United States
  • Employees
  • SGA N/A
  • HURA N/A
  • Industry
  • SGA Broadcasting
  • HURA
  • Sector
  • SGA Consumer Discretionary
  • HURA
  • Exchange
  • SGA Nasdaq
  • HURA Nasdaq
  • Market Cap
  • SGA 87.3M
  • HURA 103.3M
  • IPO Year
  • SGA 1992
  • HURA N/A
  • Fundamental
  • Price
  • SGA $13.05
  • HURA $2.58
  • Analyst Decision
  • SGA
  • HURA Strong Buy
  • Analyst Count
  • SGA 0
  • HURA 2
  • Target Price
  • SGA N/A
  • HURA $11.50
  • AVG Volume (30 Days)
  • SGA 6.7K
  • HURA 268.6K
  • Earning Date
  • SGA 08-07-2025
  • HURA 08-15-2025
  • Dividend Yield
  • SGA 7.66%
  • HURA N/A
  • EPS Growth
  • SGA N/A
  • HURA N/A
  • EPS
  • SGA 0.55
  • HURA N/A
  • Revenue
  • SGA $111,837,000.00
  • HURA N/A
  • Revenue This Year
  • SGA N/A
  • HURA N/A
  • Revenue Next Year
  • SGA $4.84
  • HURA $69.15
  • P/E Ratio
  • SGA $23.89
  • HURA N/A
  • Revenue Growth
  • SGA N/A
  • HURA N/A
  • 52 Week Low
  • SGA $10.75
  • HURA $1.80
  • 52 Week High
  • SGA $16.48
  • HURA $8.63
  • Technical
  • Relative Strength Index (RSI)
  • SGA 49.58
  • HURA N/A
  • Support Level
  • SGA $13.04
  • HURA N/A
  • Resistance Level
  • SGA $13.65
  • HURA N/A
  • Average True Range (ATR)
  • SGA 0.51
  • HURA 0.00
  • MACD
  • SGA -0.07
  • HURA 0.00
  • Stochastic Oscillator
  • SGA 27.95
  • HURA 0.00

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: